Avance Clinical Wins MasterControl 2020 Innovation Excellence Award
October 30, 2020
The leading Australian CRO for biotechs, and Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award winner, Avance Clinical today accepted the MasterControl 2020 Innovation Excellence Award in a virtual ceremony.
The leading Australian CRO for biotechs, and Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award winner, Avance Clinical today accepted the MasterControl 2020 Innovation Excellence Award in a virtual ceremony.
Avance Clinical
made the announcement today at AusBiotech 2020 (28 – 30 October, 2020).
Avance
Clinical CEO Yvonne Lungershausen said the company was very pleased to be
awarded such recognition by MasterControl, a leader in the clinical digital
management technology.
“The
award acknowledges our leadership as Australia’s biotech CRO and it provides further
confidence to our clients that we are serious about delivering quality clinical
research services by being nimble and adaptive, and by utilising
state-of-the-art systems that are compliant with industry standards, such as
MasterControl eQMS,” said Yvonne Lungershausen.
“Avance
Clinical invests significantly in the industry’s leading clinical technologies
making it one of the most advanced CROs globally for digital clinical research
management and eClinical solutions.”
On presenting
the Innovation Excellence Award, MasterControl said the award recognises
“the power of innovation and celebrates companies who feel the same way we do,
who are not afraid to shed the status quo to find their own path and who push
boundaries and spearhead important changes within their industries. Companies
driven by innovation who truly live and breathe it.”
Avance Clinical Director Quality Assurance, Priyanka Chamoli, said:
“Receiving the award from MasterControl is a testament of our commitment
to invest in our Quality Management System and to continually improve and
strengthen it. This Award recognises and provides visibility to our efforts to
push boundaries and adopt this significant change not just for the Quality
Assurance department but across-the-board in the organisation.”
“MasterControl eQMS enables accurate, streamlined processes for Document
Control and Training. Avance Clinical, which is on a significant growth
trajectory, requires robust procedures as part of our QMS. MasterControl has
allowed our staff to create/review and access our controlled documents in real-time
and the automated link between different modules enables timely delivery of
training.”
Avance Clinical Director Compliance and Training, Lisa Eglinton said:
“MasterControl Training Module provides a robust, user-friendly method
for the delivery of role-specific training programs to all staff. The
system provides a real-time indication of training status to Trainees and their
Line Managers which ensures training compliance across the company.”
Avance Clinical is the leading Australian owned CRO that has been
providing high-quality clinical research services fit for global regulatory
standards to the local and international drug development industry for 20
years.
See Image here http://bit.ly/AvanceClinicalMasterControl
(From left to right) Priyanka Chamoli, Director Quality Assurance,
Emma Woolman, Senior Compliance and Training Officer, Yvonne
Lungershausen, Avance Clinical’s CEO, and Lisa Eglinton, Director Compliance
and Training.
About Avance Clinical www.avancecro.com
Australia’s Avance Clinical has more than 20-years of experience and is now one
of Australia’s leading Contract Research Organizations.
Avance Clinical is committed to providing
high-quality clinical research services with its highly-experienced team.
The collective pool of knowledge and experience at Avance Clinical continually
grows through the careful selection of experts who also demonstrate passion in
their chosen field.
Avance Clinical offers high-quality services in an established clinical trial
ecosystem, that includes world-class Investigators and Sites able to access
specialized patient groups.
Other benefits include:
1. The Government R&D grant means up to 43.5% rebate on clinical trial
spend
2. eClinical solutions – speed and continuity
3. Site Initiation Visit (SIV) and Study Start achieved in 5 – 6 weeks
4. No IND required for clinical trials
5. Full GMP material is not mandated for Phase I clinical trials
6. Established clinical trial environment with world-class Investigators and
sites
7. Established healthy subject databases and specialized patient populations
8. Five independent Phase 1 facilities across Australia including
hospital-based units for critical care
9. Major hospitals with world-class infrastructures and dedicated Clinical Trial
Units with a long track-record in FDA compliant research
10. Seasonal studies: Northern hemisphere Sponsors can conduct their studies
year-round by taking advantage of Australia’s counter-flu and allergy seasons